Champions Oncology (CSBR) Return on Capital Employed (2011 - 2026)
Champions Oncology (CSBR) recorded quarterly Return on Capital Employed of 30.43% in Q1 2026, down 216.23% quarter-over-quarter from 26.18% in Q4 2025, and down 10842.0% on a YoY basis from N/an in Q1 2025.
Champions Oncology (CSBR) Return on Capital Employed (2011 - 2026) Analysis & Trends
Champions Oncology's Return on Capital Employed history runs 16 years deep, the most recent figure standing at 30.43% for Q1 2026.
- In Q1 2026, Return on Capital Employed fell 10842.0% year-over-year to 30.43%; the TTM figure through Jan 2026 stood at 30.43% (down 10842.0% YoY), while the FY2025 annual figure was 84.55%, up 16929.0% from the prior year.
- Return on Capital Employed was 30.43% for Q1 2026 at Champions Oncology, down from 26.18% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 77.99% in Q1 2025 to a low of 172.4% in Q1 2024.
- Historically, Return on Capital Employed has averaged 26.74% across 5 years, with a median of 12.64% in 2024.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed sank 15269 bps in 2024, then surged 25039 bps in 2025.
- A 5-year view of Return on Capital Employed shows it stood at 1.45% in 2022, then tumbled by 8104 bps to 116.39% in 2023, then jumped by 89 bps to 12.64% in 2024, then soared by 307 bps to 26.18% in 2025, then slumped by 216 bps to 30.43% in 2026.
- The last three Return on Capital Employed figures came in at 30.43% (Q1 2026), 26.18% (Q4 2025), and 30.83% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 450.31% |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 51.73% |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -107.40% |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -50.43% |
| 10 | Champions Oncology | 78.46 Mn | 71.46 Mn | 13.89 Mn | -30.43% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jan 31, 2026 | -30.43% |
| Oct 31, 2025 | 26.18% |
| Jul 31, 2025 | 30.83% |
| Apr 30, 2025 | 59.65% |
| Jan 31, 2025 | 77.99% |
| Oct 31, 2024 | -12.64% |
| Jul 31, 2024 | -54.55% |
| Apr 30, 2024 | -149.54% |
| Jan 31, 2024 | -172.40% |
| Oct 31, 2023 | -116.39% |
| Jul 31, 2023 | -64.16% |
| Apr 30, 2023 | -38.94% |
| Jan 31, 2023 | -19.70% |
| Oct 31, 2022 | 1.45% |
| Jul 31, 2022 | 2.73% |
| Apr 30, 2022 | 3.57% |
| Jan 31, 2022 | 1.69% |
| Oct 31, 2021 | 2.60% |
| Jul 31, 2021 | 1.03% |
| Apr 30, 2021 | 2.40% |